AP Biosciences Inc (TPEX:6945)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
124.50
+4.50 (3.75%)
Aug 15, 2025, 1:54 PM CST
115.77%
Market Cap 10.64B
Revenue (ttm) n/a
Net Income (ttm) -422.75M
Shares Out 85.11M
EPS (ttm) -5.61
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 2,000
Average Volume 1,012,956
Open 120.50
Previous Close 120.00
Day's Range 116.00 - 127.00
52-Week Range 36.30 - 178.00
Beta 0.74
RSI 63.71
Earnings Date Aug 8, 2025

About AP Biosciences

AP Biosciences Inc, a clinical-stage biopharmaceutical company, researches and develops bispecific antibody drugs for unmet medical needs. It develops IBI302 that is in phase III clinical trials for the treatment of neovascular age-related macular degeneration; AP505 that is in phase I clinical trials for treating solid tumors; AP203 that is in phase I clinical trial for non-small cell lung cancer, head and neck squamous cell carcinoma, and esophageal squamous-cell carcinomas; AP402, which is in in the pre-clinical research phase for breast ca... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2013
Employees 37
Stock Exchange Taipei Exchange
Ticker Symbol 6945
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.